Volume | 484,006 |
|
|||||
News | - | ||||||
Day High | 1.65 | Low High |
|||||
Day Low | 1.42 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
InflaRx NV | IFRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.46 | 1.42 | 1.65 | 1.63 | 1.45 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,342 | 484,006 | $ 1.53 | $ 741,197 | - | 1.14 - 4.92 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:36:51 | 3 | $ 1.58 | USD |
InflaRx NV Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
87.13M | 54.12M | - | 63k | -42.67M | -0.79 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
InflaRx NV News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IFRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.20 | 1.65 | 1.17 | 1.33 | 161,440 | 0.44 | 36.67% |
1 Month | 1.27 | 1.65 | 1.165 | 1.32 | 163,280 | 0.37 | 29.13% |
3 Months | 1.47 | 1.92 | 1.165 | 1.51 | 222,350 | 0.17 | 11.56% |
6 Months | 1.47 | 2.11 | 1.165 | 1.56 | 237,572 | 0.17 | 11.56% |
1 Year | 4.90 | 4.92 | 1.14 | 2.28 | 258,850 | -3.26 | -66.53% |
3 Years | 2.82 | 6.15 | 0.7762 | 3.42 | 543,380 | -1.18 | -41.84% |
5 Years | 41.61 | 42.99 | 0.7762 | 3.96 | 634,836 | -39.97 | -96.06% |
InflaRx NV Description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |